Further studies are needed to determine the clinical relevance of the lincRNA00907/miRNA-942-5p/TAOK1 axis in NASH patients and to evaluate the potential of targeting this axis for therapeutic interventions. This evidence concerns the gene TAOK1 and metabolic dysfunction-associated steatohepatitis.